Table 1: Baseline characteristics of included studies&.

StudyYearCountryNumber lost to followupFollowup (months)Intervention armsFBG (mg/dL)Duration of diabetes (years)HbA1c %Age (years)Sample size (F/M, )BMI
(kg/m2)

Dixon et al. [13]2008Australia 0 (60) 24Gastric banding + medication156 (38.5)≤27.8 (1.2)46.6 (7.4)15/1537.0 (2.7)
Medication158 (48.7)≤27.6 (1.4)47.1 (8.7)17/1337.2 (2.5)

Schauer et al. [14]2012
USA 10 (150) 12Gastric bypass193 (141, 231)*8.2 (5.5)9.3 (1.4)48.3 (8.4)29/2137.0 (3.3)
Gastrectomy164 (132, 224)*8.5 (4.8)9.5 (1.7)47.9 (8.0)39/1136.2 (3.9)
Medication155 (120, 206)*8.9 (5.8)8.9 (1.4)49.7 (7.4)31/1936.8 (3.0)

Mingrone et al. [15]2012Italy 10 (60) 24Gastric bypass9.55 (3.35)**6.03 (1.18)8.6 (1.40)43.9 (7.57)8/1244.85 (5.16)
Biliopancreatic diversion9.70 (3.44)**6.00 (1.26)8.88 (1.71)42.75 (8.06)10/1045.14 (7.78)
Medication9.94 (3.43)**6.08 (1.24)8.5 (1.24)43.4 (7.27)10/1045.62 (6.24)

means (SD); FBG: fasting blood glucose; HbA1c: hemoglobin A1c; F/M: female/male; BMI: body-mass index; IQR: interquartile range; *IQR: interquartile range; **mmol/liter.